At this year's ASH congress, the results of the phase 1b/2 DURGA-1 of AZD0120 – a dual BCMA and CD19-directed CAR-T therapy – ...

The verdict is the latest twist in patent litigation between MSD and Halozyme, in which the latter is claiming that Keytruda ...

CD19-targeted therapy Breyanzi (lisocabtagene maraleucel) can now be used to treat adults with MZL – a rare and form of ...

Protego Biopharma is poised to start pivotal trials of its amyloid light-chain (AL) amyloidosis drug candidate, thanks to a ...

Bayer has started a phase 3 trial of its intrauterine contraceptive Mirena in an endometrial condition that can lead to ...

Eli Lilly's fast-growing blood cancer drug Jaypirca has bagged a new FDA approval as an earlier treatment for relapsed or ...

These days, the phrase “omnichannel engagement” is everywhere. But the way the biopharmaceutical industry thinks about ...

The EMBOLD study of relutrigine (also known as PRAX-562) was testing the oral drug in patients with SCN2A and SCN8A ...

Seven digital health technologies (DHTs) that can be used to support people recovering from cardiovascular diseases have been ...

Despite their readiness, blood centres remain an underutilised lever in pharma’s innovation model. As industry players seek ...

Amiculum, a global health communications agency, has entered into an exciting strategic collaboration with VuuAI, a ...

For decades, contract development and manufacturing organisations (CDMOs) have operated through fragmented models, with drug ...